Expanded Indications of Molecular-Targeted Drugs in Perioperative Therapy of Breast Cancer

In recent years, numerous molecular-targeted drugs have become available for the perioperative therapy of breast cancer, bringing about a revolution in breast cancer treatment. Based on comprehensive gene expression analysis, breast cancer is classified into four subtypes, and there are limitations...

Full description

Saved in:
Bibliographic Details
Main Authors: Eiichiro Noguchi, Sadako Akashi-Tanaka
Format: Article
Language:English
Published: Society of Tokyo Women's Medical University 2024-06-01
Series:Tokyo Women's Medical University Journal
Subjects:
Online Access:https://www.jstage.jst.go.jp/article/twmuj/8/0/8_2024003/_pdf/-char/en
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846109772907020288
author Eiichiro Noguchi
Sadako Akashi-Tanaka
author_facet Eiichiro Noguchi
Sadako Akashi-Tanaka
author_sort Eiichiro Noguchi
collection DOAJ
description In recent years, numerous molecular-targeted drugs have become available for the perioperative therapy of breast cancer, bringing about a revolution in breast cancer treatment. Based on comprehensive gene expression analysis, breast cancer is classified into four subtypes, and there are limitations regarding the drugs that can be used depending on the subtype and the cancer progression. Therefore, it is necessary to identify and select the appropriate drugs for each subtype. This review explores the expanded indications of four recently available molecular-targeted drugs in breast cancer treatment.
format Article
id doaj-art-2f28d22739354c7b96296504c09bc865
institution Kabale University
issn 2432-6186
language English
publishDate 2024-06-01
publisher Society of Tokyo Women's Medical University
record_format Article
series Tokyo Women's Medical University Journal
spelling doaj-art-2f28d22739354c7b96296504c09bc8652024-12-25T02:28:56ZengSociety of Tokyo Women's Medical UniversityTokyo Women's Medical University Journal2432-61862024-06-01801910.24488/twmuj.2024003twmujExpanded Indications of Molecular-Targeted Drugs in Perioperative Therapy of Breast CancerEiichiro Noguchi0Sadako Akashi-Tanaka1Division of Breast Surgery, Department of Surgery, Tokyo Women's Medical University School of MedicineDivision of Breast Surgery, Department of Surgery, Tokyo Women's Medical University School of MedicineIn recent years, numerous molecular-targeted drugs have become available for the perioperative therapy of breast cancer, bringing about a revolution in breast cancer treatment. Based on comprehensive gene expression analysis, breast cancer is classified into four subtypes, and there are limitations regarding the drugs that can be used depending on the subtype and the cancer progression. Therefore, it is necessary to identify and select the appropriate drugs for each subtype. This review explores the expanded indications of four recently available molecular-targeted drugs in breast cancer treatment.https://www.jstage.jst.go.jp/article/twmuj/8/0/8_2024003/_pdf/-char/ensubtypecdk 4/6 inhibitorsimmune checkpoint inhibitorsanti-her2 drugparp inhibitors
spellingShingle Eiichiro Noguchi
Sadako Akashi-Tanaka
Expanded Indications of Molecular-Targeted Drugs in Perioperative Therapy of Breast Cancer
Tokyo Women's Medical University Journal
subtype
cdk 4/6 inhibitors
immune checkpoint inhibitors
anti-her2 drug
parp inhibitors
title Expanded Indications of Molecular-Targeted Drugs in Perioperative Therapy of Breast Cancer
title_full Expanded Indications of Molecular-Targeted Drugs in Perioperative Therapy of Breast Cancer
title_fullStr Expanded Indications of Molecular-Targeted Drugs in Perioperative Therapy of Breast Cancer
title_full_unstemmed Expanded Indications of Molecular-Targeted Drugs in Perioperative Therapy of Breast Cancer
title_short Expanded Indications of Molecular-Targeted Drugs in Perioperative Therapy of Breast Cancer
title_sort expanded indications of molecular targeted drugs in perioperative therapy of breast cancer
topic subtype
cdk 4/6 inhibitors
immune checkpoint inhibitors
anti-her2 drug
parp inhibitors
url https://www.jstage.jst.go.jp/article/twmuj/8/0/8_2024003/_pdf/-char/en
work_keys_str_mv AT eiichironoguchi expandedindicationsofmoleculartargeteddrugsinperioperativetherapyofbreastcancer
AT sadakoakashitanaka expandedindicationsofmoleculartargeteddrugsinperioperativetherapyofbreastcancer